Advancing oncolytic virus therapy by understanding the biology

Affiliations

¹ Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA. HLKaufman@mgh.harvard.edu.
² Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA.

Comment

Howard L Kaufman et al. Nat Rev Clin Oncol. 2021 Apr.

. 2021 Apr;18(4):197-198.

doi: 10.1038/s41571-021-00490-4.

¹ Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA. HLKaufman@mgh.harvard.edu.
² Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA.

No abstract available

Comment on

Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective.
Ramelyte E, Tastanova A, Balázs Z, Ignatova D, Turko P, Menzel U, Guenova E, Beisel C, Krauthammer M, Levesque MP, Dummer R. Ramelyte E, et al. Cancer Cell. 2021 Mar 8;39(3):394-406.e4. doi: 10.1016/j.ccell.2020.12.022. Epub 2021 Jan 21. Cancer Cell. 2021. PMID: 33482123

1. Kaufman, H. L. et al. Oncolytic viruses: a new class of immunotherapy. Nat. Rev. Drug Disc. 18, 642–662 (2015). - DOI
1. Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780–2788 (2015). - DOI
1. Andtbacka, R. H. et al. Patterns of clinical response with Talimogene laherparepvec in patients with melanoma treated in the OPTiM Phase III clinical trial. Ann. Surg. Oncol. 23, 4169–4177 (2016). - DOI
1. Kaufman, H. L. et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIC and IV melanoma. Ann. Surg. Oncol. 17, 718–730 (2010). - DOI
1. Macedo, N. et al. Clinical landscape of oncolytic virus research in 2020. J. Immunother. Cancer. 8, e001486 (2020). - DOI